NTP Logo

Annual Report for Fiscal Year 2017

Annual Report for Fiscal Year 2017
Menu
https://ntp.niehs.nih.gov/go/837832

SACATM

The Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) is a federally chartered advisory committee established on January 9, 2002 in response to the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Authorization Act of 2000 (42 U.S.C. 285l-3[d]). SACATM advises ICCVAM, the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), and the director of NIEHS and NTP regarding statutorily mandated duties of ICCVAM and activities of NICEATM. SACATM provides advice on priorities and activities related to the development, validation, scientific review, regulatory acceptance, implementation, and national and international harmonization of new, revised, and alternative toxicological test methods. The SACATM charter and current roster are available on the NTP website, and the roster for FY 2017 is listed below. SACATM typically meets once a year and members serve rotating terms of up to 4 years. Mary Wolfe, Ph.D., served as the FY 2017 designated federal officer and manager of SACATM.

SACATM met on September 18–19, 2017, at the NIH Natcher Conference Center in Bethesda, Maryland. At the meeting, Warren Casey, Ph.D., director of NICEATM, updated SACATM on the efforts to construct a strategic roadmap that would guide development of new approaches for evaluating the safety of chemicals and medical products in the United States. SACATM members expressed a generally positive response to the roadmap and provided feedback on topics related to its implementation. The topics included encouraging federal agencies and regulated industries to adopt new toxicological methods, connecting users with new tools, and establishing greater confidence in new methods.



Members of SACATM, ICCVAM, and staff from NIEHS and NTP at the September 2016 SACATM meeting

SACATM Membership Roster FY 2017

Name and Title Affiliation Term End Date
Brian Berridge, D.V.M., Ph.D., D.A.C.V.P.
Director, WW Animal Research Strategy
GlaxoSmithKline
King of Prussia, Pennsylvania
12/31/17
Michael B. Bolger, Ph.D.
Chief Scientist
Simulations Plus, Inc.
Lancaster, California
11/30/20
Kelly P. Coleman, Ph.D., D.A.B.T., R.A.C.
Distinguished Scientist and Technical Fellow
Medtronic PLC
Minneapolis, Minnesota
11/30/20
Hisham Hamadeh, Ph.D., D.A.B.T., M.B.A. Director, Comparative Biology and Safety Sciences Amgen, Inc.
Thousand Oaks, California
11/30/19
William P. Janzen
Committee Chair
Executive Director of Lead Discovery
Epizyme, Inc.
Cambridge, Massachusetts
11/20/18
Safdar A. Khan, D.V.M., M.S., Ph.D., D.A.B.V.T.
Associate Director, Global Pharmacoavigilance
Zoetis
Kalamazoo, Michigan
11/30/16
Lawrence Milchak, Ph.D., D.A.B.T.
Senior Manager, Toxicology and Strategic Services
3M
St. Paul, Minnesota
11/30/19
Pamela J. Spencer, Ph.D., D.A.B.T.
Director of Regulatory and Product Stewardship
ANGUS Chemical Company
Buffalo Grove, Illinois
11/30/19
Catherine E. Willett, Ph.D.
Director, Regulatory Toxicology, Risk Assessment and Alternatives
The Humane Society of the United States
Gaithersburg, Maryland
11/30/18
ClarLynda Williams-Devane, Ph.D.
Director, Bioinformatics, Genomics, and Computational Chemistry
Biotechnology Biomedical Research Institute
North Carolina Central University
Durham, North Carolina
11/30/20
Wei Xu, Ph.D.
Associate Professor, Department of Oncology
McArdle Laboratory for Cancer Research
University of Wisconsin at Madison
Madison, Wisconsin
11/30/18
Hao Zhu, Ph.D.
Assistant Professor, Department of Chemistry
Rutgers University
Camden, New Jersey
11/30/19